PDCD1 and melanoma: When a specific ALKBH5 inhibitor ALK-04 was used, the expression of ALKBH5 was down-regulated and the effect of anti-PD-1 therapy was enhanced, indicating that ALKBH5 can be used as a potential therapeutic target for melanoma [99].